



## RESULTS FOR THE FIRST QUARTER, 2019

- **SHAREHOLDERS TO APPROVE TOD FINANCES' INVESTMENT IN CC&C**
- **CC & C GETS CERTIFICATION BY ITS COMPETITIVENESS CLUSTER**

**Arles, May 20, 2019** - CELL CONSTRAINT & CANCER, a company specializing in the treatment of pancreatic cancer with mechanical signals, presents its review of the past period, as well as its strategic priorities for the next quarter.

### SHAREHOLDERS TO APPROVE TOD FINANCES' INVESTMENT IN CC&C

We held our General Assembly on May 9th.

This was mainly an opportunity to ratify family office "TOD Finances" investment in the company.

Concluded in March, this operation brings 100,000 euros in cash to CC&C and secures us for another one or two years, the time to obtain public funding to set up the animal experimentation that will definitively prove the therapeutic interest of our method.

### AN UPDATE ON FUNDING APPLICATIONS IN PROGRESS

We participated in the G.Force competition organized by the Gollinelli Foundation. Unfortunately, we were not selected. On the other hand, we have filed in time the following two applications:

- January 24<sup>th</sup>, at the European FET-Open window, with the NANOSTRESS consortium, led by Professor Couvineau's team in Bichat, for a total amount of € 2.8 million over 3 years. The answer is expected by the end of June, not by the end of April as announced in our last press release ([read more about the Nanostress project](#)).

- March 1, at the European FEDER window, with the MAGCELL consortium led by Professor Guari of the ICGM at the University of Montpellier. Here, our contribution will be more modest but will validate on cell cultures that a human pancreatic tumor is responding to a stress field. Answer is due in September.

In any case, the hiring of a research engineer is postponed to September: we need a funded research program before thinking of having someone work on it.

### CC & C GETS CERTIFICATION BY ITS COMPETITIVENESS CLUSTER

As an additional source of funding, we targeted the [PIA3 program](#), operated jointly by BPI France and the Regional Council Sud - PACA. [Eurobiomed](#), our competitiveness cluster in health industries, validates this choice with this certification and integrates us into its assistance program for setting up R & D project.

The orientation of the project will depend on the outcome of Nanostress. If we receive FET-Open funding, we will request this budget to conduct a quicker and cheaper Proof of Efficacy trial on the most constraint-responsive cell line (s) – excluding pancreatic cancer – in order to optimize the technical device. This will include experimental validation of the magnetic energy doses and exposure times.

If we do not get the FET-Open funding, we leave open the possibility of funding our Proof of Efficacy for pancreatic cancer with this PIA3 program, after discussion and in agreement with our scientific partners and our shareholders.

The project budget should be between 200,000 and 400,000 euros, subsidized at 50%, over one year. We anticipate a filing of the application for September.

## SHORT NEWS

We left our office in Arles at the end of March and have temporarily returned to the headquarters of the company in Raphèle-les-Arles (and teleworking) before moving to Marseille by September. Once again, the characteristics of the future office depends a lot on the result of the FET-Open.

In addition, we are starting a redesign of our communication tools including our website. It is likely that until this overhaul is completed, we will be less active and offer fewer news and fewer scientific reviews.

**Next appointment: June 30, 2019**

Find all the information on CELL CONSTRAINT & CANCER:

<http://new.cellconstraintcancer.com/>



## **About CELL CONSTRAINT & CANCER**

Founded in 2009 by Rémy BROSSEL, medical oncologist and physicist, CELL CONSTRAINT & CANCER develops innovative treatments based on physical oncology, complementary to current approaches in oncology. Addressing primarily non-metastatic non-operable tumors, such as cancer of the pancreas, brain, or liver, the company published in May 2016 a proof of concept of slowing the growth of an in vivo grafted cancer tumor, by the action of mechanical signals (read our article: [Mechanical signals inhibit growth of a grafted tumor in vivo: Proof of Concept](#)).

Major partnerships (CNRS, INSERM) and the support of its shareholders since its beginning allow us today to initiate a new phase of experiments on animals intended to provide Proof of Efficacy of this technology on unmet medical needs.

## CONTACTS

Press Relations  
Barthélémy BROSSEL  
Tél. : [+33 \(0\)6 50 22 79 64](tel:+330650227964)

Shareholders & Investors Relations  
Christine GRAU  
Tél. : [+33 \(0\)4 90 18 48 50](tel:+330490184850)